Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Investigation of Neurological Symptoms Caused by COVID-19 in Intensive Care Unit

Yasar Altun, MD a, Semra Bulbuloglu, PhD b,*, Ali Arik, MD a

a Division of Neurology, Faculty of Medicine, Adiyaman University, Adiyaman, Turkey
b Division of Surgical Nursing, Nursing Department, Faculty of Health Sciences, Istanbul Aydin University, Istanbul, Turkey

Abstract

We examined the neurological symptoms of patients treated in intensive care for COVID-19 in this study. We obtained the study data retrospectively from data records of 1,699 patients treated in the COVID-19 clinics of a training and research hospital. The study is a descriptive and cross-sectional study. Sociodemographic and Disease Information Form were used for data collection. Statistical Packed for the Social Sciences 25.0 IBM was used in Data analysis. It was observed that 37% of the COVID-19 patients were between the ages of 66–80 years and 35.6% of the COVID-19 patients were male. The most common neurological symptoms in the disease process and their rates were as follows: insomnia 74.6%, taste loss 75.6%, muscle pain 83.2%, headache 45.1%, dizziness 32.2%, weakness 20.2%, and agitation 34.7%. Assessment of neurological symptoms of patients followed up for COVID-19 is of great importance. We suggest that neurological problems should be tried to be cured with appropriate treatment protocols and therapy support before they progress further and the neurological prognosis progresses.

Introduction

COVID-19, which causes severe acute respiratory problems, is a deadly disease that first appeared in Wuhan, China in December 2019 and caused a global pandemic (Guan et al., 2020). Vaccination procedures is carried out as well as various treatment protocols in order to weaken the disease-causing mechanism of COVID-19. Despite the use of vaccines worldwide, COVID-19 continues to cause dire consequences. It was stated in a previous study that 2,246 out of 1,228,664 people who had the first two doses of vaccine were infected with COVID-19. In the same study, it was stated that 36 people died among those infected with COVID-19, and 189 of them had severe symptoms (Yek et al., 2022).

It is reported that the clinical course of COVID-19 is worse in people with cardiovascular disease (CVD), diabetes mellitus (DM), hypertension, neurological disorder, and in older people (Benussi et al., 2020; Qin et al., 2020; Zhou et al., 2020). In addition to this, people exposed to COVID-19 have a high risk of developing central nervous system (CNS)-related disorders (Glass et al., 2004). It is stated in the literature that neurological disorders may occur in the future after the acute phase of COVID-19 has been overcome (Desforges et al., 2019). The degree and severity of the course of COVID-19 are significantly associated with the development of psychiatric and neurological disorders. Severe systemic inflammatory responses are likely to induce these disorders. The neurological vulnerability of elderly, and of those with weakened immune system, comorbidities or chronic diseases is higher (Antonini et al., 2020; Bianchetti et al., 2020; Kubota, & Kuroda, 2021). Even if they survive COVID-19, even minor injuries such as urinary tract infection or pneumonia can trigger acute confusional state, confusion, delirium, and encephalopathy, as they will have residual susceptibility.

Increasing awareness of neurological symptoms caused by COVID-19 is of great importance for the management, prevention, treatment, and therapy support before they progress further and the neurological prognosis progresses.

Availability of data and material: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. 

* Corresponding author: Semra Bulbuloglu, Division of Surgical Nursing, Nursing Department, Health Sciences Faculty, Istanbul Aydin University, Florya Campus, Küçükçekmece, Istanbul, Turkey.
E-mail addresses: semrabulbuloglu@aydin.edu.tr, semrabulbuloglu@hotmail.com (S. Bulbuloglu).
and treatment of these symptoms. In addition to this, neurological symptoms seen during the treatment process of COVID-19 may be a sign of a poor neurological prognosis in the future. Negative emotional state and poor patient outcomes caused by neurological symptoms are also expected situations in this regard. Detection of neurological symptoms will enable us to make predictions regarding possible future neurological prognosis and learn about the areas the patients need support. We examined the neurological symptoms of patients treated in intensive care for COVID-19 in this study.

Materials and methods

We conducted this study as a descriptive and cross-sectional study to examine the neurological disorders experienced by patients receiving intensive care treatment for COVID-19.

Research Design and Participants

We conducted our study with the participation of patients receiving treatment in the COVID-19 intensive care of a tertiary training and research hospital in eastern Turkey. The data regarding the hospitalization of the patients included in this study were obtained from the data records after the approval of the ethics committee. All patients who were hospitalized due to COVID-19 and met the inclusion criteria were included in the study and purposive sampling method was used. A total of 1699 patients who were hospitalized due to COVID-19 between March 10, 2020 and January 31, 2022, in the hospital where the study was conducted were included in the sample. Neurological and pulmonary problems related to COVID-19, certain blood values, chronic diseases existing before COVID-19, diseases developing secondary to COVID-19, sociodemographic data of patients were extracted from patient files and recorded in data collection form. Sampling inclusion and exclusion criteria are provided below.

Inclusion Criteria

i. Diagnosis of COVID-19
ii. Being treated in the ICU due to COVID-19
iii. Age 18 years and above
iv. Not being diagnosed with any neurological disorder prior to COVID-19

Exclusion Criteria

i. Diagnosis other than COVID-19
ii. Treatment at home or out of ICU for COVID-19
iii. Patients under the age of 18 years
iv. Being diagnosed with a neurological disorder prior to COVID-19

Data Collection Tools

Sociodemographic and COVID-19 Information Form were used for data collection. The sociodemographic and COVID-19 information form is a questionnaire developed by researchers in which the personal characteristics of the patients and the problems, illnesses, symptoms, and clinical conditions they experienced during the period they had COVID-19 are investigated.

| Table 1 | Descriptive characteristics of COVID-19 patients (n = 1699) |
|---------|-------------------------------------------------------------|
| **Introductory information** | **n** | **%** |
| Age | | |
| Ages between 20 and 35 | 54 | 3.2 |
| Ages between 36 and 50 | 143 | 8.4 |
| Ages between 51 and 65 | 431 | 25.4 |
| Ages between 66 and 80 | 628 | 37 |
| 81 years old and above | 443 | 26.1 |
| Gender | | |
| Female | 755 | 44.4 |
| Male | 944 | 55.6 |
| Body Mass Index | | |
| Between 18 and 25 | 1291 | 76 |
| Between 25 and 29.9 | 351 | 20.7 |
| Between 30 and 39.9 | 52 | 3.1 |
| 40 and higher | 5 | 0.3 |
| Alcohol Consumption | | |
| Drinks | 358 | 21.1 |
| Does not drink | 1341 | 78.9 |
| Smoking Habit | | |
| Smoker | 455 | 26.8 |
| Nonsmoker | 1244 | 73.2 |
| Chronic Diseases before COVID-19 | | |
| No chronic disease | 347 | 20.4 |
| Hepatopancreato bilary diseases | 225 | 13.2 |
| Diabetes mellitus | 267 | 15.7 |
| Chronic obstructive pulmonary disease | 211 | 12.4 |
| Chronic kidney failure | 221 | 13 |
| Cardiovascular disease | 210 | 12.4 |
| Asthma | 140 | 8.2 |
| Malignity | 74 | 4.4 |
| 3 and above Comorbidity | 52 | 3.1 |
| Outcome | | |
| Those recovered from COVID-19 | 1119 | 65.9 |
| Death | 422 | 24.8 |
| Neurological Prognosis | 158 | 9.3 |

XX = Mean; SD = standard deviation.
* More than one problem was recorded in the same patient.

Statistical Analysis of Data

After the data were coded by the researchers, the statistical analysis of the data was made using the Statistical Packed for the Social Sciences (SPSS) 25.0 IBM statistical program. Descriptive statistics were used in the analysis of the data. 95% confidence interval and p < .05 error level were taken into account in the evaluation of the results obtained.

Ethical Aspect of Research

Necessary legal permissions were obtained from Adiyaman University Training and Research Hospital and the Ethics Committee of the same university before starting the research (Decree no: 2021/10-24). Data were obtained from electronic records after ethics committee approval and we did not have access to patients’ private information (name, surname, ID number, etc.).

Findings

The descriptive characteristics COVID-19 patients are listed in Table 1. It was seen that 26.1% of the COVID-19 patients were 81 and older, 37% were between the ages of 66-80 years, and 55.6% of the COVID-19 patients were male. 76% of COVID-19 patients had a body mass index of 18-25, 78.9% have not used alcohol, 73.2% have not smoked. Of the COVID-19 patients treated in the ICU, only 20.4% had no chronic disease, the remainder had various chronic diseases
Table 2
Neurological symptoms caused by COVID-19 (n = 1699)

| Symptom                          | n   | %   |
|----------------------------------|-----|-----|
| Peripheral nerve involvement     | 372 | 21.9|
| Insomnia                         | 1267| 74.6|
| Epileptic seizure                | 364 | 21.4|
| Agitation                        | 589 | 34.7|
| Confusion                        | 424 | 25.0|
| Lack of attention                | 366 | 21.5|
| Loss of taste                    | 1257| 74.0|
| Headache                         | 767 | 45.1|
| Ischemic stroke                  | 19  | 1.2|
| Blurred vision                   | 414 | 24.4|
| Dizziness                        | 547 | 32.2|
| Loss of smell                    | 1285| 75.6|
| Appetite disorder                | 259 | 15.2|
| Numbness in fingertips           | 256 | 15.1|
| Double vision                    | 118 | 6.9 |
| Muscle ache                      | 1413| 83.2|
| Weakness                          | 343 | 20.2|

Other Problems*                  
Cough                            | 1216| 71.6|
Dyspnea                          | 1201| 70.7|
GIS problems                     | 322 | 19  |
High Fever                       | 1583| 93.2|
Increase in serum CRP            | 1399| 82.3|
Increase in serum Procalcitonin  | 1528| 89.9|
Increase in serum d-Dimer        | 786 | 46.3|

* More than one problem was recorded in the same patient.

(Hepatopancreatobiliary diseases, Diabetes mellitus, Chronic obstructive pulmonary disease, etc.).

The neurological symptoms caused by COVID-19 are presented in Table 2. The most common neurological symptoms and their rates were as follows: insomnia 74.6%, taste loss 74%, smell loss 75.6%, muscle pain 83.2%, headache 45.1%, dizziness 32.2%, weakness 20.2%, and agitation 34.7%. 71.6% of COVID-19 patients had coughing, 70.7% of them had dyspnea, and 93.2% of them had high fever.

The comorbid and pulmonary diseases are presented in Table 3. It was determined that the most common pulmonary disease caused by COVID-19 was pneumonia with a rate of 54.1% and the rate of ARDS was 23.3%. When the health problems that develop secondary to COVID-19 during the ICU period are examined; it was seen that 9.2% of the patients developed CVD, 6% of them developed Acute Renal Failure, and 8.7% of them developed metabolic acidosis.

The relationship between the pulmonary diseases caused by COVID-19 and their outcome of clinical (death, discharge, and neurological issues) is shown in Figure 1.

As per Figure 1, it is seen that clinical outcomes, and pulmonary diseases had varying rates. It was established that ARDS and pneumonia patients developed the most neurological prognosis.

Discussion

Our study which was carried out with 1,699 patients diagnosed with COVID-19 who were treated at a hospital is an important source of information. We examined the neurological symptoms of patients treated for COVID-19 in this study. It was stated in a systematic review that headache, dizziness, and confusion were the most common neurological findings associated with COVID-19. It was also stated in the same systematic review that ischemic stroke, CNS problems, CVA, polynephopathy, muscle coordination weakness and encephalopathy were less common (Bubulouglu & Gurhan, 2022). The most common neurological symptoms in our study were muscle pain (83.2%), loss of smell (75.6%), insomnia (74.6%), loss of taste (74%), headache (45.1%), agitation (34.7%), dizziness (32.2%) and weakness (20.2%) and the least common neurological symptoms were ischemic stroke (1.2%), diplopia (6.9%), appetite disorder (15.2%), and fingertip numbness (15.1%). Our results are similar to those reported in the literature.

COVID-19-related neurological diseases are usually recognized when symptoms appear. Sometimes, neurological diseases or problems may delay the onset of symptoms in proportion to the location and size of the lesions in the brain, or the neurological disease may generate any symptoms. It was reported in a previous study that in people who had COVID-19, viruses remained in the CNS later on and these viruses later led to postinfectious neurological complications (Desforges et al., 2019). Our study also highlights the onset of neurological symptoms during the acute phase of COVID-19. In addition to the foregoing, it was observed that during the acute phase of COVID-19, 4.8% of the patients had a CVA and 5.5% had subdural hemorrhage. In our study, it was established that 9.3% of the patients who survived the acute phase of COVID-19 experienced neurological prognosis. Previous studies reported that neurological diseases seen in more than 30% of the patients (Karadaş, Öztürk & Sonkaya, 2020; Mao et al., 2020). The difference may be due to the fact that the diseases diagnosed with neurological symptoms were not separately specified in previous studies.

Upon review of the studies in the literature it is seen that; in a study conducted with the participation of n = 239 COVID-19 patients, it was reported that 26.7% of the patients had headaches, 6.7% of them had dizziness, 9.6% of them had confusion, 12.6% of them had sleep disturbance, and 15.1% of them had muscle pain (Karadaş, Öztürk & Sonkaya, 2020). In a study conducted in China with the participation of n = 214 patients, it was reported that 25% of the patients had CNS problems, 13% of them had headache, 17% of them had dizziness, and 8% of them had confusion (Mao et al., 2017). Case reports in the literature have generally addressed 1 or 2 findings. These findings include dramatic issues such as Guillain-Barré syndrome, ischemic stroke, encephalopathy, and cerebral venous sinus thrombosis (Alberti et al., 2020; Beyrouti et al., 2020;
In addition to that, it is stated in literature that patients with at least one neurological symptom have a significantly higher blood D-dimer level ($p < .05$) than patients without any neurological symptoms (Karadağ, Oztürk & Sonkaya, 2020). It was emphasized in literature that the level of D-dimer, leukocytes, neutrophils and C-reactive protein (CRP) increased due to COVID-19 (Li et al., 2020). Eighty-two-point three percent of the patients included in our study had an increase in CRP and 46.3% of them had an increase in D-dimer levels. Our results are similar to those reported in the literature.

It was determined that 65.9% of 1,699 COVID-19 patients included in our study recovered from COVID-19, 24.8% of them died, and 9.3% were transferred to the neurology clinic due to neurological prognosis. Patients who recovered from COVID-19 continued to struggle with the diseases they contracted during the time they had COVID-19. It was established in our study that COVID-19 plays an active role in the development of not only neurological issues, but also many other problems and diseases such as CVD, acute renal failure, metabolic acidosis, gastric bleeding, and hypoalbuminemia. COVID-19 is an extremely dangerous disease that causes mass deaths, especially before vaccination. The problems caused by COVID-19 have not been fully understood yet. Our study is an important source of information in this sense. That being said, the fact that all patients were not examined by neuroimaging methods in our study and interleukin and other cytokine values could not be checked were deemed as limitations of this study.

Conclusion

The findings of our study revealed that the neurological issues associated with COVID-19 should not be ignored and are seen at a high rate. It was found out in our study that at least one neurological finding occurred in every COVID-19 patient. Our study is an important source of information for a full understanding of the effects of COVID-19 disease. Unfortunately, due to the pandemic, not all of the available evidence could be confirmed by advanced diagnostic methods, due to financial problems and a lack of workforce. Therefore, additional studies are needed to be conducted. It should also be considered that not all COVID-19 patients undergo a neurological examination. This is an indication that some issues and symptoms may go undetected. Clinicians should be aware of possible psychiatric and neurological issues, and these issues should be diagnosed and treated at an early stage.

CRediT authorship contribution statement

Yasar Altun: Conceptualization, Data curation, Formal analysis, Interpretation, Writing — original draft, Writing — review & editing.

Semra Bulbuloglu: Conceptualization, Methodology, Data curation, Formal analysis, Interpretation, Writing — original draft, Writing — review & editing.

Ali Arik: Data curation, Formal analysis, Interpretation.

References

Alberti, P., Beretta, S., Piatti, M., Karantzoulis, A., Piatti, M.L., Santoro, P., et al. (2020). Guillian–Barre syndrome related to COVID-19 infection. Neurology-Neuroimmunology Neuroinflammation, 7(4), e741.

Antonacci, A., Leta, V., Teo, J., & Chaudhuri, K.R. (2020). Outcome of Parkinson’s disease patients affected by COVID-19. Movement Disorders, 35, 1-5.

Benussi, A., Pilotto, A., Premi, E., Libri, L., Giunta, M., Agosti, C., et al. (2020). Clinical characteristics and outcomes of inpatients with neurologic disease and COVID-19 in Brescia, Lombardy, Italy. Neurology, 95(7), e910-e920.

Beyrouti, R., Adams, M.E., Benjamin, L., Cohen, H., Farmer, S.F., Goh, Y.Y., et al. (2020). Characteristics of ischaemic stroke associated with COVID-19. Journal of Neurology, Neurosurgery & Psychiatry, 91(8), 889-891.

Bianchetti, A., Rozzini, R., Guerini, F., Boffelli, S., Raineri, P., Minelli, G., et al. (2020). Clinical presentation of COVID19 in dementia patients. The Journal of Nutrition, Health & Aging, 24(6), 560-562.

Bulbuloglu, S., & Gurhan, N. (2022). A Systematic review of detailed neurologic and psychiatric manifestations in patients with COVID-19. Journal of Psychiatric Nursing, 13(1), 92-99.

Cavalcanti, D.D., Raz, E., Shapiro, M., Dehkargarhi, S., Yaghi, S., Lillemeoe, K., et al. (2020). Cerebral venous thrombosis associated with COVID-19. American Journal of Neuroradiology, 41(8), 1370-1376.

Desforges, M., Le Coupesc, A., Dubeau, P., Bourguin, A., Lajoie, L., Dubé, M., et al. (2019). Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses, 12(1), 14.

Glass, W.G., Subbarao, K., Murphy, B., & Murphy, P.M. (2004). Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. The Journal of Immunology, 173(6), 4030-4039.

Guan, W.J., Ni, Z.Y., Hu, Y., Liang, W.H., Ou, C.Q., He, J.X., et al. (2020). Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine, 382(18), 1708-1720.
Karadas, Ö., Öztürk, B., & Sonkaya, A.R. (2020). A prospective clinical study of detailed neurological manifestations in patients with COVID-19. *Neurological Sciences, 41*(8), 1991-1995.

Kubota, T., & Kuroda, N. (2021). Exacerbation of neurological symptoms and COVID-19 severity in patients with preexisting neurological disorders and COVID-19: a systematic review. *Clinical Neurology and Neurosurgery, 200*, 106340.

Li, Y., Li, M., Wang, M., Zhou, Y., Chang, J., Xian, Y., et al. (2020). Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. *Stroke and Vascular Neurology, 5*(3), 279-284.

Mao, L., Jin, H., Wang, M., Hu, Y., Chen, Y., He, Q., et al. (2020). Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. *JAMA Neurology, 77*, 1-9.

Oxley, T.J., Mocco, J., Majidi, S., Kellner, C.P., Shoirah, H., Singh, I.P., et al. (2020). Large-vessel stroke as a presenting feature of Covid-19 in the young. *New England Journal of Medicine, 382*(20), e60.

Padroni, M., Mastrangelo, V., Asioli, G.M., Pavolucci, L., Abu-Rumeileh, S., Piscaglia, M.G., et al. (2020). Guillain-Barré syndrome following COVID-19: new infection, old complication? *Journal of Neurology, 267*(7), 1877-1879.

Paterson, R.W., Brown, R.L., Benjamin, L., Nortley, R., Wiethoff, S., Bharucha, T., et al. (2020). The emerging spectrum of COVID-19 neurology: clinical, radiological and laboratory findings. *Brain, 143*(10), 3104-3120.

Qin, C., Zhou, L., Hu, Z., Yang, S., Zhang, S., Chen, M., et al. (2020). Clinical characteristics and outcomes of COVID-19 patients with a history of stroke in Wuhan, China. *Stroke, 51*(7), 2219-2223.

Yek, C., Warner, S., Wiltz, J.L., Sun, J., Adjei, S., Mancera, A., et al. (2022). Risk factors for severe COVID-19 outcomes among persons aged ≥ 18 years who completed a primary COVID-19 vaccination series-465 health care facilities, United States, December 2020-October 2021. *Morbidity and Mortality Weekly Report, 71*(1), 19.

Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *The Lancet, 395*(10229), 1054-1062.